Zacks: Brokerages Expect Constellation Pharmaceuticals Inc (CNST) to Announce -$0.68 Earnings Per Share

Share on StockTwits

Equities analysts expect that Constellation Pharmaceuticals Inc (NASDAQ:CNST) will report earnings of ($0.68) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Constellation Pharmaceuticals’ earnings, with estimates ranging from ($0.81) to ($0.49). The firm is expected to report its next quarterly earnings report on Tuesday, November 13th.

On average, analysts expect that Constellation Pharmaceuticals will report full year earnings of ($2.88) per share for the current fiscal year, with EPS estimates ranging from ($3.48) to ($2.52). For the next fiscal year, analysts forecast that the business will post earnings of ($2.84) per share, with EPS estimates ranging from ($3.43) to ($2.51). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that cover Constellation Pharmaceuticals.

Constellation Pharmaceuticals (NASDAQ:CNST) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($9.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($9.25).

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. assumed coverage on shares of Constellation Pharmaceuticals in a research report on Monday, August 13th. They issued an “overweight” rating and a $17.00 price target for the company. BMO Capital Markets assumed coverage on shares of Constellation Pharmaceuticals in a research report on Monday, August 13th. They issued an “outperform” rating and a $19.00 price target for the company. Cann assumed coverage on shares of Constellation Pharmaceuticals in a research report on Monday, August 13th. They issued an “outperform” rating and a $21.00 price target for the company. Finally, Oppenheimer assumed coverage on shares of Constellation Pharmaceuticals in a research report on Monday, August 13th. They issued an “outperform” rating and a $21.00 price target for the company.

In other news, major shareholder Alexandria Venture Investments bought 66,667 shares of the firm’s stock in a transaction that occurred on Monday, July 23rd. The stock was bought at an average price of $15.00 per share, with a total value of $1,000,005.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Anthony B. Evnin bought 133,334 shares of the firm’s stock in a transaction that occurred on Monday, July 23rd. The shares were purchased at an average cost of $15.00 per share, with a total value of $2,000,010.00. The disclosure for this purchase can be found here. Insiders bought a total of 400,001 shares of company stock valued at $6,000,015 in the last ninety days.

Shares of CNST traded down $0.39 during mid-day trading on Thursday, hitting $8.71. The company’s stock had a trading volume of 37,067 shares, compared to its average volume of 47,048. Constellation Pharmaceuticals has a 52-week low of $8.75 and a 52-week high of $12.21.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.

See Also: Google Finance

Get a free copy of the Zacks research report on Constellation Pharmaceuticals (CNST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply